Movatterモバイル変換


[0]ホーム

URL:


AU1705100A - Blocking factor b to treat complement-mediated immune disease - Google Patents

Blocking factor b to treat complement-mediated immune disease

Info

Publication number
AU1705100A
AU1705100AAU17051/00AAU1705100AAU1705100AAU 1705100 AAU1705100 AAU 1705100AAU 17051/00 AAU17051/00 AAU 17051/00AAU 1705100 AAU1705100 AAU 1705100AAU 1705100 AAU1705100 AAU 1705100A
Authority
AU
Australia
Prior art keywords
mediated immune
immune disease
blocking factor
treat complement
complement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU17051/00A
Inventor
Gary Gilkeson
Hiroshi Watanabe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MUSC Foundation for Research and Development
Original Assignee
MUSC Foundation for Research and Development
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MUSC Foundation for Research and DevelopmentfiledCriticalMUSC Foundation for Research and Development
Publication of AU1705100ApublicationCriticalpatent/AU1705100A/en
Abandonedlegal-statusCriticalCurrent

Links

Classifications

Landscapes

AU17051/00A1998-10-091999-10-08Blocking factor b to treat complement-mediated immune diseaseAbandonedAU1705100A (en)

Applications Claiming Priority (3)

Application NumberPriority DateFiling DateTitle
US10366098P1998-10-091998-10-09
US601036601998-10-09
PCT/US1999/023485WO2000021559A2 (en)1998-10-091999-10-08Blocking factor b to treat complement-mediated immune disease

Publications (1)

Publication NumberPublication Date
AU1705100Atrue AU1705100A (en)2000-05-01

Family

ID=22296362

Family Applications (1)

Application NumberTitlePriority DateFiling Date
AU17051/00AAbandonedAU1705100A (en)1998-10-091999-10-08Blocking factor b to treat complement-mediated immune disease

Country Status (2)

CountryLink
AU (1)AU1705100A (en)
WO (1)WO2000021559A2 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US7619081B2 (en)2002-11-142009-11-17Dharmacon, Inc.siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)
US8198427B1 (en)2002-11-142012-06-12Dharmacon, Inc.SiRNA targeting catenin, beta-1 (CTNNB1)
EP2305812A3 (en)2002-11-142012-06-06Dharmacon, Inc.Fuctional and hyperfunctional sirna
US7951935B2 (en)2002-11-142011-05-31Dharmacon, Inc.siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC)
US7691998B2 (en)2002-11-142010-04-06Dharmacon, Inc.siRNA targeting nucleoporin 62kDa (Nup62)
US7977471B2 (en)2002-11-142011-07-12Dharmacon, Inc.siRNA targeting TNFα
US9839649B2 (en)2002-11-142017-12-12Thermo Fisher Scientific Inc.Methods and compositions for selecting siRNA of improved functionality
WO2006006948A2 (en)2002-11-142006-01-19Dharmacon, Inc.METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US9719092B2 (en)2002-11-142017-08-01Thermo Fisher Scientific Inc.RNAi targeting CNTD2
US9719094B2 (en)2002-11-142017-08-01Thermo Fisher Scientific Inc.RNAi targeting SEC61G
US7635770B2 (en)2002-11-142009-12-22Dharmacon, Inc.siRNA targeting protein kinase N-3 (PKN-3)
US7592442B2 (en)2002-11-142009-09-22Dharmacon, Inc.siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)
US7612196B2 (en)2002-11-142009-11-03Dharmacon, Inc.siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
US9879266B2 (en)2002-11-142018-01-30Thermo Fisher Scientific Inc.Methods and compositions for selecting siRNA of improved functionality
US9228186B2 (en)2002-11-142016-01-05Thermo Fisher Scientific Inc.Methods and compositions for selecting siRNA of improved functionality
US10011836B2 (en)2002-11-142018-07-03Thermo Fisher Scientific Inc.Methods and compositions for selecting siRNA of improved functionality
US9771586B2 (en)2002-11-142017-09-26Thermo Fisher Scientific Inc.RNAi targeting ZNF205
US7959919B2 (en)*2003-11-192011-06-14Novelmed Therapeutics, Inc.Method of inhibiting factor B-mediated complement activation
PL1713503T3 (en)*2004-02-102014-02-28Univ Colorado RegentsInhibition of factor b, the alternative complement pathway and methods related thereto
BRPI0506629A (en)2004-02-102007-05-02Univ Colorado factor b inhibition, the alternative complement system pathway and related methods
US7605250B2 (en)2004-05-122009-10-20Dharmacon, Inc.siRNA targeting cAMP-specific phosphodiesterase 4D
CA2610340C (en)2005-05-262016-02-16Vernon Michael HolersInhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
EP2236518B1 (en)2007-03-142014-08-06Alexion Cambridge CorporationHumaneered anti-factor B antibody
EP2453906A4 (en)2009-07-022014-01-15Musc Found For Res Dev METHODS FOR STIMULATING LIVER REGENERATION
US9803005B2 (en)2012-05-242017-10-31Alexion Pharmaceuticals, Inc.Humaneered anti-factor B antibody
SG10201806787VA (en)*2013-09-132018-09-27Ionis Pharmaceuticals IncModulators of complement factor b
KR102369736B1 (en)2014-05-012022-03-02아이오니스 파마수티컬즈, 인코포레이티드Compositions and methods for modulating complement factor b expression
AP2016009612A0 (en)2014-06-122016-12-31Ra Pharmaceuticals IncModulation of complement activity
HUE056613T2 (en)2015-01-282022-02-28Ra Pharmaceuticals Inc Modulators of complement activity
KR20180094913A (en)2015-12-162018-08-24라 파마슈티컬스 인코포레이티드 Regulator of complement activity
KR20190036520A (en)2016-06-272019-04-04아칠리온 파르마세우티칼스 인코포레이티드 Quinazoline and indole compounds for the treatment of medical disorders
MX2019006527A (en)2016-12-072019-08-01Ra Pharmaceuticals IncModulators of complement activity.
JP2021505565A (en)2017-12-042021-02-18ラ ファーマシューティカルズ インコーポレイテッドRa Pharmaceuticals,Inc. Modulator of complement activity
JP2022524078A (en)2019-03-082022-04-27ラ ファーマシューティカルズ インコーポレイテッド Zircoplan as a deep tissue penetrating C5 inhibitor
US20230115176A1 (en)2019-03-292023-04-13Ra Pharmaceuticals, Inc.Complement Modulators and Related Methods
AU2020261059A1 (en)2019-04-242021-10-14Ra Pharmaceuticals, Inc.Compositions and methods for modulating complement activity

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
SE9701345D0 (en)*1997-04-091997-04-09Holdingbolaget Vid Goeteborgs Transgenic, non-human animal with protein deficiency, cells derived therefrom, use of said animal and cells, and method of producing said transgenic animal

Also Published As

Publication numberPublication date
WO2000021559A2 (en)2000-04-20
WO2000021559A3 (en)2000-09-28

Similar Documents

PublicationPublication DateTitle
AU1705100A (en)Blocking factor b to treat complement-mediated immune disease
CZ20011518A3 (en)Pharmaceutical preparation
GB9801363D0 (en)Novel dosage form
AU2002225512A1 (en)Immune system stimulation
GB9804885D0 (en)Therapeutic combination
AU8495998A (en)Improved dosage units
GB9715490D0 (en)Pharmaceutical preparation
EP0907644A4 (en)Pharmaceutical preparation
PL319735A1 (en)Natural antioxidative preparation
HUP0101510A3 (en)Cosmetic preparations
PL338781A1 (en)Dosage form
AU5472899A (en)Human angiopoietin-3
AU2227999A (en)Human ependymin
AU6200799A (en)Improving immune function
GB9925432D0 (en)Virus preparation
GB9827865D0 (en)Medicament
EP1140120A4 (en)Human brainiac-5
HUP0101497A3 (en)Cosmetic preparations
GB9827285D0 (en)Medicament
GB2329335B (en)Medicament
EG25625A (en)Poly effect preparation
GB9807245D0 (en)Shearform chairs
GB9614326D0 (en)Medicament
GB9816361D0 (en)Cosmetic treatment
GB9614121D0 (en)Combined medicament

Legal Events

DateCodeTitleDescription
MK6Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase

[8]ページ先頭

©2009-2025 Movatter.jp